The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients
Abstract
Clinical observations have suggested that carnitine supplementation may be beneficial to a subset of patients receiving chronic hemodialysis. In the absence of definitive clinical trials, the clinician must decide for an individual patient whether a trial of carnitine therapy is justified. The institution of carnitine therapy is further complicated by the availability of oral and intravenous dosing forms and by the compound's complex pharmacokinetics. The oral systemic bioavailability of carnitine in normal subjects is 5% to 16%, with peak plasma carnitine concentrations reached 2 to 6 hours after dosing. Carnitine is initially distributed into extracellular water and then more slowly enters tissue compartments with complex kinetics. Elimination of carnitine is through the urine or dialysate. Intravenous carnitine administration results in large peak plasma concentrations and assures systemic bioavailability. Orally administered carnitine has been reported to have clinical efficacy in hemodialysis patients in doses of 2 to 4 g per day in divided doses. Intravenous carnitine has also been widely used in clinical trials in attempts to demonstrate efficacy in the hemodialysis population; however, the available data do not establish the superiority of the intravenous formulation over the oral form. Intravenous carnitine may have theoretical advantages in initiating treatment when high peak concentrations are required to facilitate carnitine reaching nonhepatic tissue sites or when oral carnitine therapy is not feasible due to poor tolerance or compliance. Although comparative trials are lacking, it is probable that oral therapy can be used for long-term maintenance, regardless of which formulation was used to initiate therapy. The decision to use carnitine therapy, as well as the dose and route of administration, requires individualization based on the clinical status of the patient and the goals of therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because skeletal muscle sequesters an estimated 95% of whole body carnitine reserves (17), we proceeded to survey this tissue as an indicator of systemic carnitine status.”
From Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control (2009) · cites this paper as [17]
Citations
Cites
Carnitine—metabolism and functions
Bremer, J. (1983) · Physiological Reviews · doi:10.1152/physrev.1983.63.4.1420 · Cited by 1,666
Ahmad, S., Robertson, H. T., Golper, T. A., Wolfson, M., Kurtin, P., Katz, L. A., Hirschberg, R., Nicora, R., Ashbrook, D. W., & Kopple, J. D. (1990) · Kidney International · doi:10.1038/ki.1990.290 · Cited by 193
Brevetti, G., Chiariello, M., Ferulano, G., Policicchio, A., Nevola, E., Rossini, A., Attisano, T., Ambrosio, G., Siliprandi, N., & Angelini, C. (1988) · Circulation · doi:10.1161/01.cir.77.4.767 · Cited by 175
Rebouche, C. J., & Engel, A. G. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111281 · Cited by 171
L-Carnitine and its role in medicine: from function to therapy
Ferrari, R., Mauro, S. D., & Sherwood, W. G. (1992) · Academic Press eBooks · Cited by 166
Relationship between acid-soluble carnitine and coenzyme A pools in vivo
Brass, E. P., & Hoppel, C. L. (1980) · Biochemical Journal · doi:10.1042/bj1900495 · Cited by 141
Self-citationBellinghieri, G., Savica, V., Mallamace, A., Stefano, C. D., Consolò, F., Spagnoli, L. G., Villaschi, S., Palmieri, G., Corsi, M., & Maccari, F. (1983) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/38.4.523 · Cited by 139
Golper, T. A., Wolfson, M., Ahmad, S., Hirschberg, R. R., Kurtin, P. J., Katz, L. A., Nicora, R. W., Ashbrook, D. W., & Kopple, J. D. (1990) · Kidney International · doi:10.1038/ki.1990.289 · Cited by 110
Carnitine supplementation: effect on muscle carnitine and glycogen content during exercise
VUKOVICH, M. D., COSTILL, D. L., & FINK, W. J. (1994) · Medicine & Science in Sports & Exercise · doi:10.1249/00005768-199409000-00009 · Cited by 104
Carnitine Abnormalities in Patients with Renal Insufficiency
Wanner, C., & Hörl, W. H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000185137 · Cited by 94
Cited by
Carnitine and Acylcarnitines: Pharmacokinetic, Pharmacological and Clinical Aspects
Reuter, S. E., & Evans, A. M. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261931 · Cited by 493
“Shapira Y, Glick B, Harel S, et al. Infantile idiopathic myopathic carnitine deficiency: treatment with L-carnitine.”
BackgroundInfluentialCarnitine: a nutritional, biosynthetic, and functional perspective
STEIBER, A. (2004) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2004.06.006 · Cited by 446
Stephens, F. B., Constantin‐Teodosiu, D., & Greenhaff, P. L. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2006.125799 · Cited by 396
“More than 95% of the body’s total carnitine store exists within skeletal muscle tissue (Brass, 1995), where it performs at least two known vital metabolic roles, the most well documented being the translocation of long-chain fatty acids (acyl groups) into the mitochondrial matrix for subsequent…”
BackgroundNoland, R. C., Koves, T. R., Seiler, S. E., Lum, H., Lust, R. M., Ilkayeva, O., Stevens, R. D., Hegardt, F. G., & Muoio, D. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.032888 · Cited by 317
Pharmacokinetics of L-Carnitine
Evans, A. M., & Fornasini, G. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342110-00002 · Cited by 301
Metadata
- Authors
- Brass, E.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Brass, E
- ORCID
- Brass, E
- Venue
- Clinical Therapeutics
- Publisher
- Elsevier BV
- Published
- 1995-04
- Volume
- 17
- Issue
- 2
- Pages
- 176-185
- ISSN
- 0149-2918 (ISSN-L)
- OpenAlex
- W2170085053
- Cited by
- 107
- References
- 38
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 3 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 5 · 2019: 1 · 2018: 5 · 2017: 6 · 2016: 1 · 2015: 2 · 2014: 4 · 2013: 7 · 2012: 8
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Clinical Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Nursing › Nutrition and Dietetics › Clinical Nutrition and Gastroenterology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- L-carnitine, hemodialysis, pharmacokinetics, oral bioavailability, intravenous administration, route of administration, dose selection, chronic kidney disease, personalized treatment
- MeSH terms
- Biological Availability, Carnitine, Renal Dialysis, Humans, Kidney Failure, Chronic, Muscles, Tissue Distribution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients. https://app.cochat.ai/papers/10.1016/0149-2918(95)80017-4
- The paper
- Brass, E. (1995). Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients. Clinical Therapeutics. https://doi.org/10.1016/0149-2918(95)80017-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.